glp 1 patent The Heavy Price of GLP-1 Drugs – I-MAK Ozempic's patent problem: how Novo

GLP-1 receptor agonists are widely prescribed for diabetes and obesity, populations at elevated risk for steatotic liver disease, yet fibrosis risk assessment remains inconsistently applied, delaying cirrhosis detection and management

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

GLP-1 Receptor Agonists: A Comprehensive Look at Ozempic and Mounjaro for PCOS==========================================================================GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) are generating significant buzz

Obesity management: Used widely for weight loss, even in non-diabetic individuals

Taking Ozempic or another GLP-1

2SGLT2 inhibitor labeling varies by region and individual agent with regard to indicated level of eGFR for initiation and continued use